FULC – Fulcrum Therapeutics Inc
FULC — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
8.7
Margin Of Safety %
Put/Call OI Ratio
0.17
EPS Next Q Diff
EPS Last/This Y
-0.12
EPS This/Next Y
-0.3
Price
7.83
Target Price
19
Analyst Recom
1.5
Performance Q
-27.77
Upside
-295.9%
Beta
3.37
Ticker: FULC
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | FULC | 7.93 | 0.49 | 1.55 | 9673 |
| 2026-03-10 | FULC | 8 | 0.51 | 2.27 | 9694 |
| 2026-03-11 | FULC | 7.77 | 0.51 | 999.99 | 9714 |
| 2026-03-12 | FULC | 7.63 | 0.50 | 1.68 | 9657 |
| 2026-03-13 | FULC | 7.63 | 0.50 | 1.68 | 9657 |
| 2026-03-17 | FULC | 7.41 | 0.51 | 999.99 | 9895 |
| 2026-03-18 | FULC | 6.9 | 0.55 | 0.17 | 10195 |
| 2026-03-20 | FULC | 6.81 | 0.41 | 0.94 | 11750 |
| 2026-03-25 | FULC | 6.97 | 0.21 | 0.59 | 10975 |
| 2026-03-26 | FULC | 6.93 | 0.21 | 0.17 | 10960 |
| 2026-03-27 | FULC | 6.72 | 0.21 | 0.00 | 10965 |
| 2026-03-30 | FULC | 6.56 | 0.20 | 0.00 | 11529 |
| 2026-03-31 | FULC | 7.67 | 0.19 | 0.06 | 12126 |
| 2026-04-01 | FULC | 7.47 | 0.18 | 0.00 | 12331 |
| 2026-04-06 | FULC | 7.82 | 0.18 | 1.38 | 12618 |
| 2026-04-07 | FULC | 7.83 | 0.17 | 0.00 | 12577 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | FULC | 7.93 | -7.4 | - | -1.30 |
| 2026-03-10 | FULC | 8.00 | -7.4 | - | -1.30 |
| 2026-03-11 | FULC | 7.77 | -7.4 | - | -1.30 |
| 2026-03-12 | FULC | 7.62 | -7.4 | - | -1.30 |
| 2026-03-13 | FULC | 7.65 | -7.4 | - | -1.30 |
| 2026-03-17 | FULC | 7.41 | -7.4 | - | -1.30 |
| 2026-03-18 | FULC | 6.91 | -7.4 | - | -1.30 |
| 2026-03-19 | FULC | 7.03 | -7.4 | - | -1.30 |
| 2026-03-20 | FULC | 6.81 | -7.4 | - | -1.30 |
| 2026-03-23 | FULC | 6.88 | -7.4 | - | -1.30 |
| 2026-03-24 | FULC | 6.70 | -7.4 | - | -1.30 |
| 2026-03-25 | FULC | 6.97 | -7.4 | - | -1.30 |
| 2026-03-26 | FULC | 6.93 | -7.4 | - | -1.30 |
| 2026-03-27 | FULC | 6.71 | -7.4 | - | -1.30 |
| 2026-03-30 | FULC | 6.57 | -7.4 | - | -1.30 |
| 2026-03-31 | FULC | 7.68 | -7.4 | - | -1.30 |
| 2026-04-01 | FULC | 7.47 | -7.4 | - | -1.30 |
| 2026-04-02 | FULC | 8.03 | -7.4 | - | -1.30 |
| 2026-04-06 | FULC | 7.82 | -7.4 | - | -1.30 |
| 2026-04-07 | FULC | 7.83 | -7.4 | - | -1.30 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | FULC | -29.93 | 27.53 | 6.20 |
| 2026-03-10 | FULC | -29.93 | 27.53 | 6.20 |
| 2026-03-11 | FULC | -29.93 | 27.53 | 7.43 |
| 2026-03-12 | FULC | -29.93 | 27.53 | 7.43 |
| 2026-03-13 | FULC | -29.93 | 27.53 | 7.43 |
| 2026-03-18 | FULC | -29.93 | 27.50 | 7.43 |
| 2026-03-19 | FULC | -29.93 | 27.50 | 7.43 |
| 2026-03-20 | FULC | -29.93 | 27.50 | 7.43 |
| 2026-03-23 | FULC | -29.93 | 27.50 | 7.43 |
| 2026-03-24 | FULC | -29.93 | 27.50 | 7.43 |
| 2026-03-25 | FULC | -29.93 | 27.50 | 8.70 |
| 2026-03-26 | FULC | -29.93 | 27.50 | 8.70 |
| 2026-03-27 | FULC | -29.93 | 27.50 | 8.70 |
| 2026-03-30 | FULC | -29.93 | 27.53 | 8.70 |
| 2026-03-31 | FULC | -29.93 | 27.53 | 8.70 |
| 2026-04-01 | FULC | -29.93 | 27.53 | 8.70 |
| 2026-04-02 | FULC | -29.93 | 27.53 | 8.70 |
| 2026-04-06 | FULC | -29.93 | 27.52 | 8.70 |
| 2026-04-07 | FULC | -29.93 | 27.52 | 8.70 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.31
Avg. EPS Est. Current Quarter
-0.3
Avg. EPS Est. Next Quarter
-0.31
Insider Transactions
-29.93
Institutional Transactions
27.52
Beta
3.37
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
10
Growth Score
18
Sentiment Score
67
Actual DrawDown %
76.3
Max Drawdown 5-Year %
-92.7
Target Price
19
P/E
Forward P/E
PEG
P/S
P/B
1.49
P/Free Cash Flow
EPS
-1.18
Average EPS Est. Cur. Y
-1.3
EPS Next Y. (Est.)
-1.6
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.87
Return on Equity vs Sector %
-48.9
Return on Equity vs Industry %
-32.4
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.08
EBIT Estimation
◆
FULC
Healthcare
$7.83
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
50.2
Range 1M
72.1%
Sup Dist
2%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-7.9%
EPS NY
-22.9%
52W%
40%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+142.7% upside
Upside
+142.7%
Quality
10
Fulcrum Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 55
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
FULC
Latest News
—
Caricamento notizie per FULC…
stock quote shares FULC – Fulcrum Therapeutics Inc Stock Price stock today
news today FULC – Fulcrum Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch FULC – Fulcrum Therapeutics Inc yahoo finance google finance
stock history FULC – Fulcrum Therapeutics Inc invest stock market
stock prices FULC premarket after hours
ticker FULC fair value insiders trading